A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

被引：2
|
作者：
Reagan, Patrick M.
Portell, Craig A.
Casulo, Carla
Baran, Andrea M.
Magnuson, Allison
Barr, Paul M.
Lerman, Yelena
French, Krista N.
Friedberg, Jonathan W.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140384
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [32] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [33] Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study
    Xu, Peng-Peng
    Shi, Zi-Yang
    Qian, Ying
    Cheng, Shu
    Zhu, Yue
    Jiang, Lu
    Li, Jian-Feng
    Fang, Hai
    Huang, Heng-Ye
    Yi, Hong-Mei
    Ouyang, Bin-Sheng
    Wang, Li
    Zhao, Wei-Li
    LANCET HEALTHY LONGEVITY, 2022, 3 (07): : E481 - E490
  • [34] Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study
    Wong, Helen W.
    Nguyen, Vivian H.
    Mok, Timothy Y.
    Niu, Fang
    Cushing, Merta
    Lam, Michael
    Ho, Stephanie L.
    Law, Lisa
    Aziz, Ashraf R.
    Hui, Rita L.
    BIODRUGS, 2024, 38 (04) : 601 - 610
  • [35] Prognostication of diffuse large B-cell lymphoma in the rituximab era
    Ninan, Mary J.
    Wadhwa, Punit D.
    Gupta, Pankaj
    LEUKEMIA & LYMPHOMA, 2011, 52 (03) : 360 - 373
  • [36] Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era
    Mounier, Nicolas
    Gisselbrecht, Christian
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (02) : 209 - 213
  • [37] Attenuated immunochemotherapy for diffuse large B-cell lymphoma reply
    Peyrade, Frederic
    Jardin, Fabrice
    LANCET ONCOLOGY, 2011, 12 (08): : 725 - 726
  • [38] Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma
    Shinichi Makita
    Akiko Miyagi Maeshima
    Hirokazu Taniguchi
    Hideaki Kitahara
    Suguru Fukuhara
    Wataru Munakata
    Tatsuya Suzuki
    Dai Maruyama
    Yukio Kobayashi
    Kensei Tobinai
    International Journal of Hematology, 2016, 104 : 396 - 399
  • [39] Rituximab maintenance therapy in diffuse large B-cell lymphoma
    Trajkova, S.
    Panovska-Stavridis, I.
    Stojanovik, A.
    Dukovski, D.
    Cevreska, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S23
  • [40] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
    Song, Yuqin
    Zhang, Qingyuan
    Cai, Qingqing
    Song, Yongping
    Zhang, Liling
    He, Pengcheng
    Wang, Li
    Hirata, Jamie
    Musick, Lisa
    Deng, Rong
    Liu, Wenxin
    Wang, Xin
    Zhu, Jun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (07)
12345